DP
NXTC icon

Diadema Partners’s NextCure NXTC Stock Holding History

Diadema Partners’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.4K Buy
+7,742
New +$57.2K ﹤0.01% 144

Other funds holding NXTC

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
Verdad Advisers Boston, Massachusetts $104M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Diadema Partners's NXTC Position: Q2 2026 in Review

Diadema Partners opened a new position in NextCure (NXTC) in Q2 2026: 7,742 shares worth $12.4K. The stake represents ﹤0.01% of the portfolio and ranks #144 among its holdings.

30 funds tracked by Wall St. Rank hold NXTC as of Q2 2026.

  • Diadema Partners held 7,742 shares of NextCure worth $12.4K as of Q2 2026.
  • NextCure was a new Diadema Partners position in Q2 2026.
  • NextCure made up ﹤0.01% of Diadema Partners's portfolio in Q2 2026, its #144 holding.
  • 30 funds tracked by Wall St. Rank held NextCure as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.